Podcasts

On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Videos

Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

HER2m NSCLC an “Exciting Area of Active Investigation,” Says Dr Ticiana Leal

Articles

The Institute for Value-Based Medicine series visits Texas Oncology in Austin. 

Shifting Landscape of Care Delivery  Is Impacting Value-Based Cancer Care

Despite the Hospital Transparency Rule being in effect, the majority of 340B hospitals are not reporting their prices for top services and drugs, and those that have, reported on “egregious” markups, said Ted Okon, MBA, executive director, Community Oncology Alliance.

Ted Okon on 340B Hospitals Reporting on Prices for Services and Drugs

To ensure patients will use digital health solutions, they need to be at the table when these tools are being designed, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.

Dr Amila Patel on Designing Digital Health Solutions With the Patient in Mind 

The ruling by the Supreme Court on 340B reimbursements was narrow, but it sets up a future reimbursement reduction by HHS that is even greater based on survey data, said Ted Okon, MBA, executive director, Community Oncology Alliance.

Ted Okon Explains the Narrow SCOTUS Ruling on 340B Reimbursements

There are some similarities among various value-based payment programs for cancer care, but they are not identical, said Susan Escudier, MD, FACP, vice president, value-based care and quality programs, Texas Oncology.

Dr Susan Escudier Reviews Value-Based Payment Programs in Cancer Care

The involvement of pharmacy benefit managers (PBMs) in 340B is the “colliding of 2 worlds,” said Ted Okon, MBA, executive director, Community Oncology Alliance.

Ted Okon Discusses the Impact of PBM Involvement in 340B

Telemedicine visits can make physicians more efficient, but the ability to report symptoms can add to the workload burden as staff try to figure out which symptoms need to be addressed, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.

Dr Susan Escudier on the Benefits and Burdens of Digital Health Solutions

Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.

IVBM All Coverage